What's Going On With TG Therapeutics Stock?

Zinger Key Points
  • TG Therapeutics shares are trading lower Tuesday, though the stock remains up 18% over the past five days.
  • The company acquired a worldwide license to Precision's allogeneic CD19 CAR T cell therapy program.

TG Therapeutics, Inc. TGTX shares are trading lower Tuesday, though the stock remains up 18% over the past five days. Here's a look at what's going on.

What To Know:

TG Therapeutics announced that it has entered into an agreement with Precision BioSciences, Inc. (NASDAQ GS: DTIL) to acquire a worldwide license to Precision's Azercabtagene Zapreleucel (azer-cel), an allogeneic CD19 CAR T cell therapy program for autoimmune diseases and all other non-oncology indications.

Under the terms of the agreement, TG Therapeutics will receive exclusive worldwide rights to develop and commercialize azer-cel in non-oncology indications and in exchange, Precision will receive upfront and potential near-term payments valued at $17.5 million.

"We are excited to expand our autoimmune portfolio and leverage our robust drug development and commercialization expertise in partnering with Precision on this CAR T program. We look forward to exploring azer-cel's potential to be a meaningful therapy for patients with various autoimmune disorders with a target IND filing mid-2024," said Michael S. Weiss, CEO of TG Therapeutics.

According to data from Benzinga Pro, TG Therapeutics shares are trading above the stock's 50-day moving average of $13.90, and 29.7% of shares are being sold short which may be contributing to the stock's recent price volatility.

Related News: What's Going On With BioCryst Pharmaceuticals Stock?

TGTX Price Action: According to Benzinga Pro, TG Therapeutics shares are down 5.2% at $20.19 at the time of publication.

Image: Arek Socha from Pixabay

Market News and Data brought to you by Benzinga APIs
Comments
Loading...
Posted In: NewsMoverswhy it's moving
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!